Roivant Sciences Ltd. $ROIV Shares Purchased by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 20.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 112,252 shares of the company’s stock after purchasing an additional 19,100 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Roivant Sciences were worth $4,105,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. raised its stake in Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after acquiring an additional 1,286,464 shares during the period. Perceptive Advisors LLC lifted its holdings in Roivant Sciences by 3.8% during the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after purchasing an additional 300,000 shares during the last quarter. Bank of America Corp DE boosted its position in Roivant Sciences by 8.0% during the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. Janus Henderson Group PLC boosted its position in Roivant Sciences by 6.1% during the first quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after purchasing an additional 177,339 shares during the period. Finally, Jennison Associates LLC boosted its position in Roivant Sciences by 26.7% during the first quarter. Jennison Associates LLC now owns 2,982,799 shares of the company’s stock worth $82,624,000 after purchasing an additional 629,413 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $36.31, for a total transaction of $7,262,000.00. Following the transaction, the chief executive officer owned 999,154 shares in the company, valued at $36,279,281.74. This trade represents a 16.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total value of $640,775.00. Following the completion of the transaction, the director directly owned 14,954 shares of the company’s stock, valued at $539,839.40. This represents a 54.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,022,688 shares of company stock valued at $73,438,636 over the last 90 days. 8.80% of the stock is owned by corporate insiders.

Roivant Sciences Stock Down 4.2%

Shares of ROIV opened at $36.62 on Friday. Roivant Sciences Ltd. has a 12 month low of $19.79 and a 12 month high of $42.50. The firm’s 50 day moving average is $36.66 and its 200-day moving average is $31.72.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts anticipate that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ROIV. Guggenheim increased their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 24th. Citigroup lifted their target price on shares of Roivant Sciences from $46.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, HC Wainwright increased their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and an average target price of $46.55.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.